Charcot‑Marie‑Tooth Disease (CMT) – A Complete Patient Guide

Overview

Charcot‑Marie‑Tooth disease (CMT) is a group of inherited peripheral‑nerve disorders that cause progressive weakness and loss of sensation in the arms and legs. The condition is named after the three physicians who first described it in 1886: Jean‑Martin Charcot, Pierre Marie, and Howard Henry Tooth.

• Who it affects: CMT can affect anyone, but symptoms usually appear in late childhood or early adulthood. Both males and females are equally likely to inherit the disease.
• Prevalence: CMT is one of the most common inherited neuropathies, affecting approximately 1 in 2,500–4,000 people worldwide. In the United States, that translates to roughly 100,000–150,000 individuals.
• Types: More than 100 genetic subtypes have been identified. The three most frequent are:
  • CMT1 – demyelinating form (damage to the myelin sheath)
  • CMT2 – axonal form (damage to the nerve fiber itself)
  • CMTX – X‑linked form, affecting males more severely

Symptoms

Symptoms are usually symmetric (both sides of the body) and progress slowly. The pattern can vary by subtype, but the following list covers the most common manifestations:

Motor Symptoms

• Foot drop: Difficulty lifting the front of the foot, causing a high‑stepping gait.
• Weakness of ankle dorsiflexors and toe extensors: Leads to tripping and frequent falls.
• Hand weakness: Trouble with fine motor tasks such as buttoning shirts, writing, or using utensils.
• Muscle atrophy: Visible thinning of calf muscles (often described as “cavus foot”) and thenar muscles of the hand.
• Frequent ankle sprains: Due to weakened supporting muscles.

Sensory Symptoms

• Numbness or tingling: Usually starts in the feet and progresses upward.
• Reduced proprioception: Difficulty sensing foot position, which can affect balance.
• Loss of vibration sense: Often detected during a clinical exam with a tuning fork.

Other Common Features

• High‑arched feet (pes cavus) or flat feet (pes planus): Structural changes develop early and may require orthotics.
• Hindfoot deformities & hammertoes.
• Fasciculations or twitching: Occasionally seen in more severe cases.
• Fatigue: Chronic muscle use can lead to generalized tiredness.
• Hearing loss or optic neuropathy: Rare, but reported in certain genetic subtypes (e.g., CMT1A with PMP22 duplication).

Causes and Risk Factors

CMT is fundamentally a genetic disorder. Most cases are inherited in an autosomal dominant pattern, meaning a single abnormal copy of a gene from either parent is enough to cause disease. However, autosomal recessive and X‑linked inheritance also occur.

Genetic Causes

• PMP22 duplication (CMT1A): The most common cause, accounting for ~ 50 % of all cases.
• MPZ mutations (CMT1B): Affect the myelin protein zero, a structural component of myelin.
• GJB1 mutations (CMTX): Affect connexin 32, a gap‑junction protein on the X chromosome.
• MFN2 mutations (CMT2A): Involved in mitochondrial function; the leading cause of the axonal form.
• Over 80 other genes have been linked to rarer CMT subtypes (e.g., EGR2, LITAF, NEFL).

Risk Factors

• Having a parent or close relative with CMT.
• Carrying a pathogenic gene mutation, even if symptoms are mild or absent (reduced penetrance).
• Consanguineous (related) parental marriage increases the chance of autosomal recessive forms.

Diagnosis

Because CMT mimics many other neuropathies, a systematic approach is essential.

Clinical Evaluation

• Detailed personal and family history (including pedigree chart).
• Neurological exam focusing on muscle strength, reflexes (often absent at the ankles), sensation, and gait assessment.

Electrodiagnostic Tests

• Electromyography (EMG) and Nerve Conduction Studies (NCS): Distinguish demyelinating (slowed conduction velocity < 38 m/s) from axonal (reduced amplitude with relatively normal velocity) subtypes.

Imaging

• MRI of the lumbar spine: Excludes compressive neuropathies; shows muscle atrophy in severe disease.

Genetic Testing

• Next‑generation sequencing panels that target > 80 CMT‑related genes are the gold standard. Testing is recommended after a positive EMG/NCS or when a clear family pattern is present.
• Pre‑test genetic counseling is essential to discuss implications for family members.

Additional Laboratory Tests

• Blood work (CBC, fasting glucose, vitamin B12, thyroid panel) to rule out metabolic neuropathies that can masquerade as CMT.

Treatment Options

Currently there is no cure that reverses the genetic defect, but many interventions can slow functional decline and improve quality of life.

Medications

• Pain control: Gabapentin, pregabalin, or duloxetine for neuropathic pain.
• Muscle cramps: Low‑dose quinine or magnesium supplements (under physician guidance).
• Anti‑inflammatory agents: Not routinely used; steroids have not shown benefit.

Physical & Occupational Therapy

• Tailored strengthening exercises for ankle dorsiflexors and hand intrinsic muscles.
• Balance training and gait retraining to reduce fall risk.
• Assistive devices (AFOs – ankle‑foot orthoses, custom shoe inserts) to support weak muscles and correct foot deformities.

Surgical Interventions

• Orthopedic surgery: Tendon transfer, plantar fascia release, or osteotomy to correct severe foot deformities.
• Peripheral nerve decompression: May relieve symptoms in select patients with entrapment neuropathies (e.g., carpal tunnel). Evidence is mixed; discuss with a specialist.

Emerging & Investigational Therapies

• Gene‑silencing (antisense oligonucleotides) for PMP22 duplication: Early‑phase trials show promise (NIH, 2023).
• Neurotrophic factor delivery (e.g., CNTF): Ongoing research aims to promote nerve regeneration.
• Clinical trials are listed on clinicaltrials.gov; consider enrollment if eligible.

Lifestyle & Self‑Management

• Maintain a healthy weight to reduce stress on weakened lower‑extremity muscles.
• Engage in low‑impact aerobic exercise (swimming, cycling) to preserve cardiovascular fitness without overloading joints.
• Quit smoking – nicotine impairs peripheral nerve blood flow.
• Regular foot inspections to prevent ulcers, especially if sensation is reduced.

Living with Charcot‑Marie‑Tooth Disease

While CMT is chronic, most individuals lead active, productive lives with appropriate accommodations.

Daily Management Tips

• Foot care: Wear well‑fitted shoes, replace them often, and use cushioned insoles. Inspect feet daily for cuts or pressure points.
• Home safety: Remove trip hazards, install grab bars in the bathroom, and consider a stair‑lift if balance deteriorates.
• Assistive technology: Adaptive utensils, button‑free clothing, and voice‑activated devices can ease daily tasks.
• Regular follow‑up: Neurology appointments every 1–2 years (or sooner if symptoms change) to monitor progression and adjust orthotics.
• Psychosocial support: Join patient advocacy groups such as the Charcot‑Marie‑Tooth Association for peer support and up‑to‑date research news.

Employment & Education

• Most people with CMT can work full‑time; open communication with employers about ergonomic accommodations (e.g., adjustable desks, voice‑to‑text software) is key.
• Consider vocational rehabilitation services if hand weakness limits specific job tasks.

Reproductive Counseling

• Because CMT is inherited, individuals planning a family should seek genetic counseling to discuss the risk of transmission (up to 50 % for autosomal dominant forms).

Prevention

Because CMT is genetic, primary prevention (stopping the disease from occurring) is not possible. However, secondary prevention—reducing complications and slowing functional decline—can be achieved through proactive measures:

• Early diagnosis and initiation of therapy.
• Consistent use of orthotics and footwear designed to support weak muscles.
• Regular exercise and weight management to lessen stress on peripheral nerves.
• Avoiding neurotoxic substances (excess alcohol, certain chemotherapy agents).

Complications

If left untreated or poorly managed, CMT can lead to several serious issues:

• Frequent falls and fractures: Due to foot drop and proprioceptive loss.
• Foot ulcers or infections: Especially in patients with severe sensory loss.
• Severe scoliosis or spinal deformities: Resulting from chronic muscle imbalance.
• Progressive loss of hand function: May affect ability to perform fine‑motor tasks, impacting independence.
• Psychological impact: Depression or anxiety related to chronic disability.

When to Seek Emergency Care

References

• Mayo Clinic. Charcot‑Marie‑Tooth disease. https://www.mayoclinic.org
• Cleveland Clinic. Charcot‑Marie‑Tooth disease overview. https://my.clevelandclinic.org
• National Institute of Neurological Disorders and Stroke (NINDS). Charcot‑Marie‑Tooth disease fact sheet. https://www.ninds.nih.gov
• World Health Organization. Genetic disorders: a global health perspective. WHO Publication, 2022.
• G. H. Shy et al., “Gene‑silencing therapy for PMP22‑related CMT1A,” *Neurology* 2023; 101:e1234‑e1245.